ArticleMolecular biology reports2026
Nicotinamide N-methyltransferase gene silencing is associated with upregulation of X-inactive specific transcript and downregulation of stemness-related transcription factors in ovarian cancer.
Article in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundX-inactive specific transcript (Xist), a long non-coding RNA and MacroH2A1, a histone variant are primarily involved in maintaining the inactive X chromosome in females. Xist downregulation was correlated with augmented cancer cell invasion, migration, cancer stemness and the reactivation of certain X-linked genes in ovarian cancer. Nicotinamide N-methyltransferase (NNMT) is increasingly associated with tumor progression and cancer stem cell enrichment as well as epithelial-mesenchymal transition (EMT). However, a potential relationship between NNMT and Xist, MacroH2A1 alongside stem cell mediating transcription factors (NANOG, Oct4, SOX2) and the EMT marker SNAI1 has not been previously explored.
methodsOVCAR-3 and SKOV-3 ovarian cancer cell lines were treated with NNMT siRNA or the NNMT inhibitor JBSNF-000088. Expression of Xist, NANOG, Oct4, SOX2, SNAI1, MacroH2A1 and NNMT were analyzed via RT qPCR and Western Blotting. Invasion and migration assays were performed using the xCELLigence RTCA system. Database analyses assessed Xist expression, survival and methylation correlations.
resultsNNMT silencing significantly increased Xist and MacroH2A1 expression, while decreasing NANOG, Oct4, SOX2, and SNAI1 (p < 0.05). NNMT silencing decreased invasion and migration capabilities of cancer cells (p < 0.001).
conclusionThese findings suggest a potential link between NNMT expression, cancer stemness, and Xist regulation in ovarian cancer cell lines. Upregulation of Xist and decrease in the levels of stemness and EMT factors following NNMT silencing may be associated with a more favorable molecular profile. The concurrent increase in MacroH2A1 expression supports the potential role of NNMT in modulating X chromosome reactivation in ovarian cancer possibly through the repressive effects of pluripotency factors on Xist.
Indexed as
Identifiers
41511664What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.